NASDAQ : ELDN
Eledon Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.77 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 225.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 16.72M | 16.98M | 18.61M | 12.69M | 13.10M | 13.43M |
| Research & Development | 67.89M | 66.27M | 51.96M | 30.31M | 26.68M | 23.43M |
| Operating Expenses | 84.60M | 83.25M | 70.58M | 43.00M | 39.78M | 36.87M |
| Operating Income | -84.60M | -83.25M | -70.58M | -43.00M | -39.78M | -36.87M |
| Other Non Operating Income (Expenses) | -13.92M | 37.67M | 34.82M | -73.54M | 462.00K | 7.00K |
| EBT Excluding Unusual Items | -98.53M | -45.58M | -35.75M | -116.54M | -39.32M | -36.86M |
| Impairment of Goodwill | -48.65M | |||||
| Pretax Income | -98.53M | -45.58M | -35.75M | -116.54M | -87.97M | -36.86M |
| Income Tax Expense | 35.00K | 35.00K | 431.00K | -2.35M | ||
| Net Income | -98.56M | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
| Net Income to Common | -98.56M | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
| Shares Outstanding (Basic) | 99.89M | 81.95M | 48.66M | 24.74M | 14.29M | 14.82M |
| Shares Outstanding (Diluted) | 99.89M | 81.95M | 48.66M | 24.74M | 14.29M | 14.82M |
| EPS (Basic) | -0.99 | -0.56 | -0.74 | -4.71 | -6.16 | -2.33 |
| EPS (Diluted) | -0.99 | -0.56 | -0.74 | -4.71 | -6.16 | -2.33 |
| Free Cash Flow | -73.86M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Free Cash Flow Per Share | -0.74 | -0.76 | -0.97 | -1.60 | -1.99 | -1.95 |
| EBITDA | -36.86M | |||||
| D&A For EBITDA | 5.00K | |||||
| EBIT | -84.60M | -83.25M | -70.58M | -43.00M | -39.78M | -36.87M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.80M | 22.81M | 20.55M | 4.61M | 56.41M | 84.83M |
| Short-Term Investments | 81.95M | 110.53M | 119.63M | 46.49M | ||
| Cash & Short-Term Investments | 88.76M | 133.34M | 140.18M | 51.10M | 56.41M | 84.83M |
| Other Receivables | 427.00K | 514.00K | 625.00K | |||
| Receivables | 427.00K | 514.00K | 625.00K | |||
| Prepaid Expenses | 3.53M | 1.83M | 2.82M | 4.94M | 3.08M | 3.48M |
| Other Current Assets | 382.00K | 11.00K | 104.00K | 90.00K | 28.00K | 34.00K |
| Total Current Assets | 93.09M | 135.69M | 143.73M | 56.13M | 59.52M | 88.35M |
| Property, Plant & Equipment | 445.00K | 613.00K | 926.00K | 365.00K | 739.00K | 768.00K |
| Goodwill | 48.65M | |||||
| Other Intangible Assets | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M |
| Other Long-Term Assets | 172.00K | 322.00K | 363.00K | 186.00K | 150.00K | 400.00K |
| Total Assets | 126.09M | 169.01M | 177.41M | 89.07M | 92.79M | 170.55M |
| Accounts Payable | 3.21M | 3.63M | 5.83M | 967.00K | 2.20M | 1.81M |
| Accrued Expenses | 8.19M | 14.36M | 5.43M | 2.54M | 3.91M | 2.22M |
| Current Portion of Leases | 381.00K | 358.00K | 314.00K | 383.00K | 363.00K | 369.00K |
| Total Current Liabilities | 11.79M | 18.34M | 11.58M | 3.90M | 6.47M | 4.40M |
| Long-Term Leases | 86.00K | 283.00K | 640.00K | 383.00K | 400.00K | |
| Long-Term Deferred Tax Liabilities | 2.19M | 2.19M | 2.18M | 1.75M | 1.75M | 1.75M |
| Other Long-Term Liabilities | 40.00M | 11.42M | 44.87M | 76.21M | ||
| Total Liabilities | 54.06M | 32.23M | 59.27M | 81.86M | 8.61M | 6.55M |
| Common Stock | 39.10M | 55.77M | 55.75M | 24.00K | 14.00K | 14.00K |
| Additional Paid-In Capital | 504.90M | 482.19M | 417.95M | 270.89M | 287.03M | 278.88M |
| Retained Earnings | -471.86M | -401.20M | -355.59M | -319.40M | -202.87M | -114.90M |
| Comprehensive Income & Other | -114.00K | 24.00K | 26.00K | |||
| Total Common Equity | 72.03M | 136.78M | 118.14M | -48.49M | 84.18M | 164.00M |
| Shareholders' Equity | 72.03M | 136.78M | 118.14M | 7.21M | 84.18M | 164.00M |
| Total Liabilities & Equity | 126.09M | 169.01M | 177.41M | 89.07M | 92.79M | 170.55M |
| Total Debt | 467.00K | 641.00K | 954.00K | 383.00K | 746.00K | 769.00K |
| Net Cash (Debt) | 88.29M | 132.69M | 139.22M | 50.72M | 55.66M | 84.06M |
| Net Cash Per Share | 0.88 | 1.62 | 2.86 | 2.05 | 3.90 | 5.67 |
| Filing Date Shares Outstanding | 81.26M | 75.85M | 59.88M | 24.81M | 13.78M | 14.31M |
| Total Common Shares Outstanding | 80.97M | 75.54M | 59.90M | 24.21M | 13.78M | 14.31M |
| Working Capital | 81.30M | 117.34M | 132.15M | 52.23M | 53.04M | 83.94M |
| Book Value Per Share | 0.89 | 1.81 | 1.97 | -2.00 | 6.11 | 11.46 |
| Tangible Book Value | 39.65M | 104.39M | 85.75M | -80.87M | 51.80M | 82.96M |
| Tangible Book Value Per Share | 0.49 | 1.38 | 1.43 | -3.34 | 3.76 | 5.80 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -98.56M | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
| Depreciation & Amortization | 359.00K | 374.00K | 373.00K | 195.00K | ||
| Asset Writedown & Restructuring Costs | 48.65M | |||||
| Loss (Gain) From Sale of Investments | -1.33M | -1.70M | -2.80M | -1.20M | ||
| Stock-Based Compensation | 10.25M | 10.45M | 13.12M | 6.54M | 8.15M | 7.90M |
| Other Operating Activities | 17.82M | -33.13M | -30.48M | 76.21M | -2.35M | |
| Change in Accounts Payable | -1.38M | 6.72M | 7.75M | -2.60M | 2.08M | 2.14M |
| Change in Other Net Operating Assets | -663.00K | 928.00K | 959.00K | -2.32M | 287.00K | -2.29M |
| Operating Cash Flow | -73.86M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Investment in Securities | 21.14M | 10.79M | -70.31M | -45.29M | ||
| Investing Cash Flow | 21.14M | 10.79M | -70.31M | -45.29M | ||
| Issuance of Common Stock | 53.78M | 53.81M | 133.52M | 33.02M | 1.00K | |
| Other Financing Activities | -450.00K | |||||
| Financing Cash Flow | 53.78M | 53.81M | 133.52M | 33.02M | -449.00K | |
| Net Cash Flow | 1.06M | 2.26M | 15.94M | -51.80M | -28.42M | -29.36M |
| Free Cash Flow | -73.86M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Free Cash Flow Per Share | -0.74 | -0.76 | -0.97 | -1.60 | -1.99 | -1.95 |
| Levered Free Cash Flow | -45.10M | -33.66M | -21.40M | -24.47M | -13.85M | -15.33M |
| Unlevered Free Cash Flow | -45.10M | -33.66M | -21.40M | -24.47M | -13.85M | -15.33M |
| Change in Working Capital | -2.04M | 7.65M | 8.71M | -4.92M | 2.37M | -152.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 213.11M | 113.47M | 246.13M | 43.56M | 31.37M | 63.09M |
| Enterprise Value | 124.83M | 20.80M | 168.44M | -15.57M | -33.68M | -30.73M |
| Last Close Price | 2.77 | 1.51 | 4.12 | 1.80 | 2.28 | 4.41 |
| PB Ratio | 3.11 | 0.83 | 2.08 | 6.04 | 0.37 | 0.39 |
| P/TBV Ratio | 5.33 | 1.09 | 2.87 | 0.61 | 0.76 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.05 | 0.01 | 0.01 |
| Net Debt / Equity Ratio | -1.23 | -0.97 | -1.18 | -7.04 | -0.66 | -0.51 |
| Net Debt / EBITDA Ratio | 2.28 | |||||
| Net Debt / FCF Ratio | 1.20 | 2.13 | 2.94 | 1.28 | 1.96 | 2.91 |
| Quick Ratio | 7.57 | 7.30 | 12.16 | 13.12 | 8.71 | 19.28 |
| Current Ratio | 7.90 | 7.40 | 12.41 | 14.41 | 9.19 | 20.07 |
| Return on Equity (ROE) | -110.71% | -35.79% | -57.73% | -255.03% | -70.89% | -19.46% |
| Return on Assets (ROA) | -39.02% | -30.04% | -33.11% | -29.56% | -18.88% | -12.53% |
| Return on Capital Employed (ROCE) | -74.00% | -55.30% | -42.60% | -50.50% | -46.10% | -22.20% |
| Earnings Yield | -37.66% | -40.20% | -14.70% | -267.55% | -280.45% | -54.69% |
| FCF Yield | -34.92% | -54.94% | -19.21% | -90.75% | -90.62% | -45.83% |
| Buyback Yield / Dilution | -44.49% | -68.42% | -96.70% | -73.17% | 3.61% | -921.03% |